查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611687

非鴉片類疼痛治療市場規模、佔有率和趨勢分析報告：按藥物類別、疼痛、給藥途徑、通路、地區和細分市場預測，2025-2030

Non-opioid Pain Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Pain, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

非鴉片類疼痛治療市場的成長與趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，全球非鴉片類疼痛治療市場規模將達到703億美元，2025年至2030年複合年成長率為7.69%。

這種成長是由發炎性疾病的日益普及以及新型非鴉片類鎮痛藥的強大產品平臺所推動的。根據美國疾病管制與預防中心 (CDC) 的數據，美國約有 3,250 萬人患有骨關節炎，根據美國的數據，美國約有 320 萬人患有某種形式的脊椎關節病變。

各國政府和非營利組織正在努力推廣使用更安全的鴉片類藥物替代品，例如非類固醇抗發炎藥，以滿足對止痛藥物不斷成長的需求。例如，2022年2月，美國FDA發布指南草案，建議製藥公司開發NSAIDs來治療持續30天的急性疼痛。該舉措是政府 HHS過量攝取預防策略的一部分，該策略的重點是預防、減少、治療鴉片類藥物過量攝取並從中恢復。預計此類措施將在預測期內推動對非類固醇抗發炎藥的需求。

市場主要參與企業正在積極開發創新技術，以滿足對非類固醇抗發炎藥物用於疼痛管理不斷成長的需求。例如，2021 年 6 月，亞利桑那大學開發了一種催產素類似物，用於治療患病患者。它是一種生物可利用的非鴉片類鎮痛藥，可以透過吸入給藥。此類創新產品的開發預計將推動非鴉片類鎮痛治療市場的成長。

2022年9月，美國FDA建議懷孕20週時避免使用非鴉片類止痛治療，因為這會增加胎兒腎臟損傷的風險。這些政府措施可能會限制非類固醇抗發炎藥的配方，從而限制非鴉片類鎮痛藥市場的成長。

公司正在採用新產品開發、商業發布和合作夥伴關係等策略來提高非鴉片類鎮痛藥的滲透率。例如，2022 年 3 月，Vertex Pharmaceuticals 宣布一項 2 期臨床試驗的積極結果表明，非鴉片類藥物錠劑可顯著減輕術後急性疼痛。成功的臨床實驗和隨後的產品核准預計將在預測期內推動非鴉片類鎮痛治療市場的成長。

該市場競爭激烈，參與企業數量眾多，預計預測期內市場競爭將處於高水準。生產非專利抗發炎藥學名藥的主要企業包括 GSK plc.、Sun Pharmaceutical Industries Ltd.、Novartis AG、Teva Pharmaceutical Industries Ltd.、Viatris Inc. 和 Johnson & Johnson Services, Inc.。

非鴉片類疼痛治療市場的報告亮點

  • 2024年，NSAIDs細分市場佔據最大的市場佔有率，並且由於近年來對疼痛治療和多種NSAIDs商業化的高需求，預計在預測期內將保持其主導地位。
  • 到 2024 年，慢性疼痛比例將最高。產品核可增加、慢性疼痛的高盛行率以及推出創新非類固醇消炎劑產品的高研發舉措等因素導致了這一優勢。
  • 按給藥途徑類型分類，口服非類固醇抗發炎藥產品在 2024 年佔據最高佔有率，因為口服非類固醇抗發炎藥產品易於給藥且在市場上廣泛使用。
  • 從分銷管道來看，零售藥局預計將在 2024 年以 54.39% 的佔有率佔據市場主導地位。這一優點是由於有大量非非專利非類固醇消炎劑可供選擇，並且患者可以透過強大的零售藥房網路輕鬆獲得這些藥物。
  • 由於新興國家非類固醇抗發炎藥產品滲透率的提高、可支配收入的增加以及發炎性疾病的盛行率較高，預計亞太地區將在預測期內經歷最快的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章非鴉片類鎮痛治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 非鴉片類疼痛治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 價格分析

第4章 非鴉片類鎮痛治療市場：依藥物類別估計與趨勢分析

  • 細分儀表板
  • 全球非鴉片類鎮痛治療市場：藥物類別變化分析
  • 按藥品和類別分類的收益
  • NSAID
    • 非選擇性非類固醇抗發炎藥
    • 選擇性COX-2抑制劑
  • 乙醯胺酚
  • 局部麻醉劑
  • 其他

第5章 非鴉片類鎮痛治療市場：依疼痛類別估計與趨勢分析

  • 細分儀表板
  • 全球非鴉片類鎮痛治療市場：疼痛波動分析
  • 痛苦，收益
  • 術後疼痛
  • 癌症痛
  • 慢性疼痛
  • 其他疼痛

第6章 非鴉片類鎮痛治療市場：依給藥途徑的估計與趨勢分析

  • 細分儀表板
  • 全球非鴉片類鎮痛治療市場：給藥途徑變化分析
  • 按管理途徑分類的收益
  • 口服
  • 局部的
  • 注射
  • 其他

第7章 非鴉片類鎮痛治療市場：按分銷管道估計和趨勢分析

  • 細分儀表板
  • 全球非鴉片類鎮痛治療市場：通路波動分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章非鴉片類鎮痛治療市場：按藥物類別、鎮痛、給藥途徑和分銷管道分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 2024年主要企業市場佔有率分析
    • Novartis AG
    • Teva Pharmaceutical Industries Limited
    • Sun Pharmaceutical Industries Ltd
    • GSK plc.
    • Pfizer Inc.
    • Perrigo Company plc.
    • LNK International, Inc.
    • Cipla Inc.
    • Johnson & Johnson Services, Inc.
    • Pacira Pharmaceuticals, Inc.
    • Pierrel
Product Code: GVR-4-68039-983-1

Non-opioid Pain Treatment Market Growth & Trends:

The global non-opioid pain treatment market size is expected to reach USD 70.30 billion by 2030, registering a CAGR of 7.69% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis.

Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government's "HHS Overdose Prevention Strategy" which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period.

Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth.

In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth.

Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period.

The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others.

Non-opioid Pain Treatment Market Report Highlights:

  • In 2024, the NSAIDs segment accounted for the largest market share and is anticipated to maintain its dominance over the forecast period owing to the high demand for pain treatment and the commercialization of multiple NSAIDs in recent years
  • Chronic pain was the accounted for highest share in 2024. Factors such as increasing product approvals, the high incidence rate of chronic pain, and high R&D initiatives for launching innovative NSAIDs products are leading to its dominance
  • Based on route of administration type, the oral segment accounted for the highest share in 2024 owing to the easy administration and wide availability of orally administered NSAIDs products in the market
  • Based on the distribution channel, retail pharmacies are expected to dominate the market with a 54.39% share in 2024. This dominance can be attributed to the presence of a large number of generic NSAIDs and their easy accessibility to patients due to the large presence of retail pharmacies network
  • Asia Pacific region is expected to experience the fastest growth during the forecast period owing to an increase in penetration of NSAIDs products, rise in disposable income, and high disease prevalence of inflammatory diseases in developing countries

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Pain
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class and pain outlook
    • 2.2.2. Route of administration and distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Non-opioid Pain Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of chronic & inflammatory diseases globally
      • 3.2.1.2. Increasing product approvals and launches
      • 3.2.1.3. Supportive regulatory and reimbursement policies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations
      • 3.2.2.2. Side-effects associated with drug
  • 3.3. Non-opioid Pain Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis

Chapter 4. Non-opioid Pain Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Non-opioid Pain Treatment Market: Drug Class Movement Analysis
  • 4.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Drug, Class Revenue (USD Million)
  • 4.4. NSAIDs
    • 4.4.1. NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non-Selective NSAIDs
      • 4.4.2.1. Non-Selective NSAIDs market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Selective COX-2 Inhibitors
      • 4.4.3.1. Selective COX-2 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Acetaminophen
    • 4.5.1. Acetaminophen market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Local Anesthetics
    • 4.6.1. Local Anesthetics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Drug Class
    • 4.7.1. Others drug class market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-opioid Pain Treatment Market: Pain Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Non-opioid Pain Treatment Market: Pain Movement Analysis
  • 5.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Pain, Revenue (USD Million)
  • 5.4. Post-operative Pain
    • 5.4.1. Post-operative pain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cancer Pain
    • 5.5.1. Cancer pain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Chronic Pain
    • 5.6.1. Chronic pain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Other Pain
    • 5.7.1. Other pain market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-opioid Pain Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Non-opioid Pain Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Topical
    • 6.5.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Injectable
    • 6.6.1. Injectable market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Other Route of Administration
    • 6.7.1. Other route of administration market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Non-opioid Pain Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Non-opioid Pain Treatment Market: Distribution Channel Movement Analysis
  • 7.3. Global Non-opioid Pain Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 7.4. Hospitals Pharmacies
    • 7.4.1. Hospitals pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Non-opioid Pain Treatment Market: Regional Estimates & Trend Analysis By Drug Clas, Pain, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company market share analysis, 2024
    • 9.3.2. Novartis AG
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Product benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Teva Pharmaceutical Industries Limited
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Product benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Teva Pharmaceutical Industries Limited
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Sun Pharmaceutical Industries Ltd
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. GSK plc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Pfizer Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Perrigo Company plc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. LNK International, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Cipla Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Johnson & Johnson Services, Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Pacira Pharmaceuticals, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Pierrel
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 List of key distributors
  • Table 4 List of other companies
  • Table 5 List of key emerging company's/technology disruptors/innovators
  • Table 6 North America Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 8 North America Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 9 North America Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 12 U.S. Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 13 U.S. Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 16 Canada Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 17 Canada Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 20 Mexico Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 21 Mexico Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Europe Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 24 Europe Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 25 Europe Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 26 Europe Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Europe Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 UK Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 29 UK Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 30 UK Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 UK Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Germany Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 33 Germany Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 34 Germany Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Germany Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 France Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 37 France Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 38 France Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 France Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Spain Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 41 Spain Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 42 Spain Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Spain Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Italy Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 45 Italy Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 46 Italy Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Italy Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Denmark Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 49 Denmark Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 50 Denmark Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Denmark Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Sweden Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 53 Sweden Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 54 Sweden Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Norway Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 57 Norway Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 58 Norway Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 Norway Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Japan Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 65 Japan Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 66 Japan Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Japan Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 China Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 69 China Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 70 China Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 China Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 India Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 73 India Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 74 India Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 India Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Australia Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 77 Australia Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 78 Australia Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 Australia Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 South Korea Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 81 South Korea Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 82 South Korea Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 South Korea Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 Thailand Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 85 Thailand Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 86 Thailand Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 Thailand Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Latin America Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 89 Latin America Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 90 Latin America Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 91 Latin America Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Latin America Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 93 Brazil Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 94 Brazil Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 95 Brazil Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Brazil Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 97 Argentina Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 98 Argentina Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 99 Argentina Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 100 Argentina Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 101 MEA Non-Opioid Pain Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 102 MEA Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 103 MEA Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 104 MEA Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 105 MEA Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 106 South Africa Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 107 South Africa Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 108 South Africa Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 109 South Africa Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 111 Saudi Arabia Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 114 UAE Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 115 UAE Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 116 UAE Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 117 UAE Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Non-Opioid Pain Treatment Market, By Drug Class Class, 2018 - 2030 (USD Million)
  • Table 119 Kuwait Non-Opioid Pain Treatment Market, By Pain, 2018 - 2030 (USD Million)
  • Table 120 Kuwait Non-Opioid Pain Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Non-Opioid Pain Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Non-opioid pain treatment market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Non- opioid pain treatment market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Non- opioid pain treatment market driver impact
  • Fig. 14 Non- opioid pain treatment market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's Five Forces
  • Fig. 17 Strategy mapping
  • Fig. 18 Non-opioid pain treatment market: Drug class outlook and key takeaways
  • Fig. 19 Non- opioid pain treatment market: Drug class movement analysis & market share 2024 & 2030
  • Fig. 20 NSAIDs non-opioid treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Non-selective NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Selective COX-2 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Acetaminophen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Local Anesthetics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other drug class market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Non-opioid treatment market: Pain outlook and key takeaways
  • Fig. 27 Non-opioid treatment market: Pain movement analysis & market share 2024 & 2030
  • Fig. 28 Post-operative pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Cancer pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Other pain non-opioid treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Non- non-opioid treatment market: Distribution channel outlook and key takeaways
  • Fig. 33 Non- non-opioid treatment market: Distribution channel movement analysis & market share 2024 & 2030
  • Fig. 34 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Global Non-opioid Pain Treatment market: Regional movement analysis
  • Fig. 38 Global Non-opioid Pain Treatment market: Regional outlook and key takeaways
  • Fig. 39 Global Non-opioid Pain Treatment market share and leading players
  • Fig. 40 North America, by country
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Mexico key country dynamics
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Market share Analysis of key market players, 2024